Status:
COMPLETED
Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden
Lead Sponsor:
Uppsala University
Collaborating Sponsors:
Karolinska University Hospital
Sahlgrenska University Hospital
Conditions:
Covid19
Myeloma Multiple
Eligibility:
All Genders
18+ years
Brief Summary
This retrospective observational cohort study aims to describe the impact of COVID-19 in patients treated with autologous stem cell transplantation (ASCT) for malignant disease in terms of risk factor...
Detailed Description
Research question How does infection with SARS-CoV-2 affect patients with hematological malignancies who are treated with autologous hematopoietic stem cell transplantation? Study population All Swed...
Eligibility Criteria
Inclusion
- Diagnosis of hematological cancer (C81-C96 according to the International Classification of Diseases 10th revision (ICD-10).
- Autologous hematopoietic stem cell transplantation performed 1 January 2020 until 31st December 2020 at a Swedish transplantation center.
- Positive RT-PCR test for SARS-CoV-2 performed in Sweden
Exclusion
- \- Age below 18 years and 0 months at the time of transplantation
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04760184
Start Date
April 1 2021
End Date
December 31 2021
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uppsala Universitet
Uppsala, Sweden